MUMBAI, India, July 5 -- Intellectual Property India has published a patent application (202517057316 A) filed by Neurimmune Ag, Schlieren, Switzerland, on June 14, for 'pharmaceutical compositions for treating or preventing transthyretin-mediated amyloidosis.'
Inventor(s) include Michalon, Aubin; and Salzmann, Michael.
The application for the patent was published on July 4, under issue no. 27/2025.
According to the abstract released by the Intellectual Property India: "Transthyretin (TTR) is a soluble protein involved in thyroxin and retinol transport in the body. Under specific conditions the TTR protein adopts misfolded, misassembled and/or aggregated TTR conformations and becomes toxic, which can lead to transthyretin-mediated amyloidosis (ATTR). Provided herein are, inter alia, compositions (e.g., pharmaceutical compositions) and related articles of manufacture that contain an anti-TTR antibody or antigen fragment thereof. Additionally, provided herein are, inter alia, methods of treating or preventing ATTR using the pharmaceutical compositions described herein."
The patent application was internationally filed on Nov. 15, 2023, under International application No.PCT/EP2023/081874.
Disclaimer: Curated by HT Syndication.
